Heart plaque Dx co gets $17m
This article was originally published in Clinica
Burlington, Massachusetts-based InfraReDx has raised $17m in new capital to initiate commercialisation of its near-infrared, catheter-based diagnostics system for detecting arterial plaque. The financing round, the company's third to date, was led by Sanderling Ventures and included the participation of new and existing individual investors, according to VentureWire. InfraReDx is expecting its technology to help prevent a second heart attack in patients who have already suffered a coronary event. The company is planning a limited roll-out of the system pending FDA approval, which is expected this quarter.